CureVac N.V. Form 6-K (June 16, 2021)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of June, 2021, Commission File Number 001-39446. It states that on June 16, 2021 the company issued a press release announcing the release of the results from the second interim analysis of its pivotal Phase 2b/3 study (HERALD study) for its first-generation COVID-19 vaccine candidate, CVnCoV. The press release is listed as Exhibit 99.1, and the report is signed by Franz-Werner Haas, LLD, LLM, Chief Executive Officer.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CureVac N.V. Form 6-K (June 16, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2021-06-16-0001104659-21-082045-16931eb32f/
, SHA-256 a056fe9933ce864322330d5abc744517e373ece5f3d80b1be6da139e151f3b8a.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2021 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x | Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ¨ | No x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ¨ | No x On June 16, 2021, CureVac N.V. (the “Company”) issued a press release announcing the release of the results from the second interim analysis of its pivotal Phase 2b/3 study (HERALD study) for its first-generation COVID-19 vaccine candidate, CVnCoV. The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: June 16, 2021 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated June 16, 2021.
File and source
- File
- SEC_CVAC_6-K_filed2021-06-16_0001104659-21-082045.htm
- Size
- 13,114 bytes
- SHA-256
- a056fe9933ce864322330d5abc744517e373ece5f3d80b1be6da139e151f3b8a
- Original
- www.sec.gov